Holen Sie sich die Stockscreener-App
4.24
0.31%
-0.0131
Handel nachbörslich:
4.15
-0.09
-2.12%
Schlusskurs vom Vortag:
$4.2531
Offen:
$4.1892
24-Stunden-Volumen:
6,644
Relative Volume:
0.31
Marktkapitalisierung:
$6.54M
Einnahmen:
$2.54M
Nettoeinkommen (Verlust:
$-4.13M
KGV:
-1.5418
EPS:
-2.75
Netto-Cashflow:
$-4.11M
1W Leistung:
+9.84%
1M Leistung:
+4.31%
6M Leistung:
+2.17%
1J Leistung:
+21.14%
1-Tages-Spanne:
$4.1045
$4.28
1-Wochen-Bereich:
$3.81
$4.32
52-Wochen-Spanne:
$2.78
$5.20
Xenetic Biosciences Inc Stock (XBIO) Company Profile
Firmenname
Xenetic Biosciences Inc
Sektor
Branche
Telefon
781-778-7720
Adresse
945 CONCORD ST., FRAMINGHAM, MA
Vergleichen Sie XBIO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XBIO
Xenetic Biosciences Inc
|
4.24 | 6.54M | 2.54M | -4.13M | -4.11M | -2.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Xenetic Biosciences Inc Stock (XBIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-01-08 | Eingeleitet | Maxim Group | Buy |
Xenetic Biosciences Inc Aktie (XBIO) Neueste Nachrichten
XBIOW (Xenetic Biosciences) Operating Income : $-4.36 Mil (TTM As of Sep. 2024) - GuruFocus.com
XBIOW (Xenetic Biosciences) Dividend Yield % : 0.00% (As of Jan. 13, 2025) - GuruFocus.com
XBIOW (Xenetic Biosciences) Cash Flow from Financing : $0.00 Mil (TTM As of Sep. 2024) - GuruFocus.com
Short Interest in Xenetic Biosciences Inc (NASDAQ:XBIO) Drops By 93.8% - Defense World
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment - Voice Of Alexandria
Xenetic Biosciences Advances Revolutionary DNase Cancer Treatment Platform with UVA Partnership - StockTitan
Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform - AccessWire
Xenetic Biosciences Extends Breakthrough Cancer Research Program with UVA Through 2025 - StockTitan
Xenetic Biosciences shareholders elect directors, approve auditor By Investing.com - Investing.com UK
Xenetic and PeriNess partner for cancer treatment trials By Investing.com - Investing.com Canada
Xenetic and PeriNess partner for cancer treatment trials - Investing.com
Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program - AccessWire
Xenetic Biosciences Partners with PeriNess to Advance Breakthrough Cancer Treatment Program - StockTitan
Xenetic Biosciences (STU:3XB0) Momentum Rank : 8 (As of Dec. 04, 2024) - GuruFocus.com
Xenetic Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Xenetic Biosciences Inc (NASDAQ:XBIO) Short Interest Down 43.2% in November - Defense World
HC Wainwright Reiterates Neutral Rating for Xenetic Biosciences (NASDAQ:XBIO) - Defense World
Xenetic Bio's DNase I Shows Breakthrough in Colorectal Cancer Treatment Efficacy | XBIO Stock News - StockTitan
XBIOXenetic Biosciences, Inc. Latest Stock News & Market Updates - StockTitan
Xenetic presents preclinical data on DNase I with CAR T cells in murine model - TipRanks
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis - AccessWire
Xenetic Bio's DNase I + CAR T Cell Therapy Shows Breakthrough in Melanoma Treatment | XBIO Stock News - StockTitan
Xenetic Biosciences Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Xenetic reports Q3 EPS (28c) vs. (69c) last year - TipRanks
Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results - AccessWire
Xenetic Bio Q3: R&D Costs Drop 64% as DNase Cancer Program Advances | $6.8M Cash | XBIO Stock News - StockTitan
Xenetic Biosciences: Q3 Earnings Snapshot - Houston Chronicle
Xenetic presents preclinical data on DNase platform technology - TipRanks
Xenetic Biosciences, Inc. Presents Positive Data Demonstrating DNase I Significantly Improves Efficacy of Anti-CTLA-4 Immune Checkpoint Blockade in Preclinical Colorectal Carcinoma Models - Oil City Derrick
Xenetic's DNase I Breakthrough Boosts Cancer Immunotherapy Efficacy in Preclinical Study | XBIO Stock News - StockTitan
Xenetic Biosciences Extends Research Collaboration with The Scripps Research Institute - Defense World
Xenetic extends research collaboration with Scripps Research Institute - TipRanks
Xenetic Biosciences Expands Collaboration for Cancer Treatment - TipRanks
Xenetic Biosciences, Inc. Extends Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform - AccessWire
Xenetic Biosciences announces board member changes By Investing.com - Investing.com Australia
Xenetic Biosciences announces board member changes - Investing.com India
Short Interest in Xenetic Biosciences Inc (NASDAQ:XBIO) Grows By 460.0% - Defense World
Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024 - AccessWire
SEC Form S-3 filed by Xenetic Biosciences Inc. - Quantisnow
Xenetic Biosciences, Inc. Enters into Materials Transfer Agreement with Tokyo Medical University for the Advancement of Its DNase-Based Oncology Platform - AccessWire
Finanzdaten der Xenetic Biosciences Inc-Aktie (XBIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.65%
4.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):